Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01718743 · ClinicalTrials.gov registry record · Phase 2
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT01718743: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01718743 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01718743, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving ixazomib citrate together with lenalidomide may be effective in treating multiple myeloma.
Interventions
- OTHER Questionnaire Administration
- DRUG Lenalidomide
- DRUG Ixazomib Citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2012-12-03 |
| Est. Completion | 2023-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01718743
The ClinicalTrials.gov registry entry for NCT01718743 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT01718743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01718743 about?
NCT01718743 is a clinical study titled "Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma". This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such a...
What is the current status of trial NCT01718743?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2012-12-03. Estimated completion is 2023-04-12.
What interventions are being tested in trial NCT01718743?
The interventions under investigation include: Questionnaire Administration (OTHER), Lenalidomide (DRUG), Ixazomib Citrate (DRUG).
Who is sponsoring clinical trial NCT01718743?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.